Exchange: NASDAQ·Updated 04:15 PM EST
PGEN logo

PGEN Precigen Inc

$4.27
$0.02
(0.47%)
Today
Closed $4.27
$0.00
(0.00%)
After Hours
Reported EarningsNov 4
Mkt Cap$1.54B
Vol4.26M

About PGEN

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
41

Bearish Sentiment

How do you feel about PGEN?

JackFrost25
$PGEN $INO What does that say about Inovio management that they didn't collect durability data prospectively and now cannot use it in promoting the drug?. 5 patients used alternative treatments in Year 2 and 4 were lost to follow-up. Trash. It is academic at this point. Inovio cannot utilize Year 2 data in promotional materials and sales reps cannot discuss it with surgeons. 5 year Papzimeos durability data vs. 1 year Voceryq durability data. That is all that matters in the real world. Game over.
2
7
RaphaelRapoport
$PGEN I am ready for PGEN board to just become about PGEN again and climb up based on PGEN accomplishments. $70M Quarterly ER is fantastic. Cash flow positive. And years as first market mover in a space that desperately needs it. Great management team, great commercialization strategy which was implemented beautifully and I expect 100M next quarter and continued growth YoY.
10
biotech
CITIZENS $PGEN Weakness following competitor approval is stark overreaction and presents compelling opportunity to buy $PGEN PAPZIMEOS complete response rate of 51% compared to 27% complete response rate achieved with VOCERYQ $INO PAPZIMEOS label also #broader than VOCERYQ
11
BlakeCanyon54
$PGEN INO still needs to issue offering & process of commercialization. These aren’t light switches that get flipped from one day to the next.
1
8
zackplanet42
$PGEN Just a quick few extra thoughts: Q3 '26 EPS (fully diluted) = $0.08 Forward PE ratio (zero growth) = 13.6 If Q4 '26 EPS = $100M => EPS = ~$0.14 That would conservatively put share price mid $7 with the same 13.6 PE ratio. Following that trend, even with significantly slowing growth, 2027 Revenue could easily hit $500M or $9.30/share fully diluted, holding PE constant (13.6). Keep in mind, 13.6 is a pretty rock bottom Forward PE ratio for biotech, even with newfound competition. 25x – 40x is more typical for a mid-cap biotech with a developing product portfolio and as evidence, that's literally where PGEN was trading very recently. Any pipeline progress should really help fuel a return to more agressive valuations. INO isn't exactly tearing things up post-approval. The recent price action here feels more like a loss in faith than a fully reasoned thesis. Feel free to tear apart my napkin math. I'm always down for a reasoned debate.
8
SellasgpsCurativeBAT11
$PGEN $SLS $INO Percigen had very good earnings yesterday and became cash flow positive first time in Co. history now down 20% 😳 ✌️🙏❤️‍🩹
1
7
Nonong
$PGEN wellover 500 have begun treatment and 300 completed. patients that’s 230mill until EOy so do the math and we are only beginning of Nov
10
GA09
$PGEN Picked up some shares this morning on the sell-off. They already have an edge by being 1st to market and already have access to patients who are already using their product with great results and they have the cash and thus no dilution. This is the classic sell-off before they release earnings this week (which will be stellar) and would not be surprised they guide higher. INO still has a lot of work ahead of it. PGEN's platform was also recently approved by the FDA and they are awaiting approval from Europe. Maybe their partner Merck will acquire them given the sell-off.
1
7
Lookingdown
$PGEN $INO Actually, mid-dosing surgical debulking is not included on the Voceryq label. Per the FDA Prescribing Information, Voceryq only requires surgical debulking prior to Dose 1 to establish minimal residual disease—no additional surgeries are part of the 9-week regimen. Mid-dosing removal of visible papillomas (prior to Doses 3 and 4) is specifically part of the Papzimeos label, not Voceryq’s. While surgeons may choose to do cleanups in real-world practice at their own discretion, it isn't part of Voceryq's FDA-approved instructions.
9
yjsw
$PGEN Q3 2026 13F fillings are out today. For me, the most important shareholders of PGEN to follow are Kirk, PCM, and Bill Miller, who together control ~200M shares (or equiverlent). Two other institutional investors worth watching are Tang Capital and Boxer Capital, since both are considered as biotech / life sciences specialists. PCM trimmed its holdings of PGEN by 5.7%. Boxer reduced its holdings by 16%. Kirk, Bill Miller, and Tang retained their Q2 2026 positions. Note that in Q3, PGEN appreciated significantly over Q2, and was traded at or near 5-year high for a period of time. Even after trimming, their (PCM and Boxer) holdings of PGEN likely worth way more than that of Q2 in absolute $. Overall, in Q3 2026, major shareholders of PGEN did some profit taking and/or portforlio re-balancing, but largely retained their positions.
7
forgottenchuck
$PGEN last quarter i predicted 50 million and they did 54 million. everybody laugh at me before earnings came out. lets see how i do today. maybe im reaching a little bit at 150 million. but you dont need many patients to achieve the goal
9
zackplanet42
$PGEN Feels like a shakeout. Going after stop-losses for cheap shares before the ER this afternoon. We've seen a very consistent drop into and then pop out of every ER since Papzimeos approval.
9
bradleytrading
$PGEN the entire argument about post drug surgery needs is ridiculous one. If a patient needs additional surgery they'll get it if they don't they won't. No surgeon is going to do a surgery when no surgery is needed no matter what the label says. If you read between the lines INO drug patients might even need more surgeries overall than papzimeos patients
8
Bordeaux17
$PGEN If I'm a patient facing a $460,000 life-changing treatment decision, I'm looking at two things: What percentage of patients achieve complete response? How long does that response last? Everything else, pales in comparison. 
8
yjsw
$PGEN "Precigen’s RRP business alone at approximately $11 per share", according to Patient Capital Management's notes on Nov. 6, 2026 (available on PCM's website).
8
Bearly_Bullish_Trader
$PGEN I think shorts see this as the last opportunity to pull down and cover before cancer trial feedback blows this outta the water, or EU approval. Retail can be faked out on ER beats. That's what they're going for. I doubled my position.
8
1of402Phase2TrialUSA
$PGEN $INO Inovio did a number on Precigen. $1.4 billion in market cap lost since FDA approval of Ino-3107. To think Precigen could have bought 51% ownership in Inovio for less than $50 million in stock. CEO of Precigen so full of herself missed the forest thru the trees.
8
forgottenchuck
$PGEN and lets not forget about news on the cancer trial and the european approval coming soon
8
CoronaNLyme
Reminder — even if $PGEN comes in AT consensus revenue $72M this quarter, that imputes a Nine-month go forward MODEST GROWTH 1yr revenue (includes this Q3 number) of …. $400M Four. Hundred. Million. @ 85% Margin That’s $340 Million of PROFIT just on Papzimeos. Then add in the Head/Neck, Cervical, KEYTRUDA combo success implication, EMA Approval… Think about All that for a minute.
8
CR2013
$PGEN Because Precigen has a 51% complete response rate, it has a vastly superior "cost-per-cure profile. Unless Inovio aggressively undercuts Precigen on price-perhaps offering risk-sharing agreements where the insurer gets a refund if the patient requires surgery within a year-Precigen is highly likely to dominate preferred status on insurance formularies. Inovio's stock surge reflects the excitement of an FDA approval, but it has likely underestimated how fiercely insurers will restrict access to a $300,000 drug with a 27% complete response rate when a 51% alternative exists.
1
5

Advertisement|Remove ads.